Repositorio Digital de la UPF
Publicación
Artículo científico (JournalArticle)
PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity
Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc-driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a KrasG12D-driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease., This work was supported by the following grants: Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grants PI20/00625 and PI23/00591 (P.N.); Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) grant PI19/00514 (C.G.); Carmen Delgado/Miguel Pérez Mateo Grants-Asociación Cancer de Páncreas and Asociación Española de Pancreatología (P.N., C.G., and J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU/AEI /10.13039/501100011033, co-funded by the European Union) grant PID2023-146049OB-I00 (J.Y.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2021-127710OB-I00 (A.J.); Spanish Ministry of Science, Innovation, and Universities (MICIU) grant PID2022-136973OB-I00 (M.R.); Cancer Research Innovation in Science (CRIS) Cancer Foundation (Excellence Grant) (M.R.); Ramón y Cajal Research Fellowship grant RYC2018-025244-I (A.J.); Ministerio de Ciencia, Tecnología e Innovación (Redes Federales de Alto Impacto) (G.A.R.); and Sales and Baron Foundations (G.A.R.).